Recent

% | $
Quotes you view appear here for quick access.

Endocyte, Inc. Message Board

  • naked_finger naked_finger Apr 18, 2012 1:02 AM Flag

    Catalysts

    RBC Capital sees several upcoming catalysts for Endocyte, including the resumption of Doxil supply in Q4; and an agreement with the FDA on a Phase III statistical plan in Q3. The firm continues to view the stock as a “compelling investment.”

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $240M cash and $60M market cap for what Merck just paid $120M upfront to be a part of. Does it need a catalyst?

      • 1 Reply to cash2go
      • EC145: Folate-Receptor Targeted Chemotherapy
        Phase 3 PROCEED trial for patients with platinum-resistant ovarian cancer: currently enrolling.
        Phase 2 PRECEDENT trial for patients with platinum-resistant ovarian cancer: enrollment complete.
        Phase 2 trial for patients with non-small cell lung cancer (NSCLC): currently enrolling.
        Phase 2 trial for patients with non-small cell lung cancer (NSCLC): enrollment complete.
        Phase 2 trial for patients with ovarian cancer: enrollment complete.
        EC17: Folate-Receptor Targeted Hapten
        Phase 1 renal (kidney) cell carcinoma trial: enrollment complete.
        EC0225: Folate-Receptor Targeted Chemotherapy
        Phase 1 solid tumor trial: enrollment complete.
        EC0489: Folate-Receptor Targeted Chemotherapy
        Phase 1 solid tumor trial: enrollment complete.

        http://www.endocyte.com/?page_id=23

        milestone payments

 
ECYT
5.27-0.01(-0.19%)Aug 31 4:00 PMEDT